Who Supplies Heparin to India from UNITED ARAB EMIRATES

Importing finished pharmaceutical formulations containing Heparin into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting Form 40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Certificate of Analysis (CoA), and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. For Heparin formulations under HS Code 30049099, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing evidence of Good Manufacturing Practice (GMP) certification from the manufacturing facility.

Upon arrival in India, each batch of Heparin formulations must undergo quality testing at a CDSCO-approved laboratory. This includes verifying the CoA, conducting stability studies in accordance with ICH Zone IV guidelines, and ensuring the product meets the standards set by the Indian Pharmacopoeia. Port inspections by customs drug inspectors are mandatory to confirm compliance with these requirements. If a batch fails to meet the prescribed standards, it may be subject to rejection, re-exportation, or destruction, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Additionally, bilateral agreements between India and the United Arab Emirates have facilitated smoother trade relations, including mutual recognition of GMP certifications, which may expedite the import process for Heparin formulations.

India imports finished Heparin formulations to meet the demand for specific dosage forms and patented or branded products not manufactured domestically. The domestic capacity for Heparin production is limited, leading to a reliance on imports to fulfill market needs. The Indian market for Heparin formulations is substantial, with a total export market value of $352.8 million across 391 exporters to 137 countries.

The import of Heparin formulations under HS Code 30049099 is subject to a Basic Customs Duty (BCD) of 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable, resulting in a total landed duty of approximately 23.536% when including the Social Welfare Surcharge (SWS) of 10%. There are no specific exemptions or preferential tariff rates for imports from the United Arab Emirates.

India sources Heparin formulations from the United Arab Emirates due to the availability of patented formulations and specialized dosage forms not produced domestically. The United Arab Emirates's share in India's Heparin import market is approximately 0.14%, with a total import value of $503 from a single shipment. Other major suppliers include China, Germany, and the United States, which collectively hold a larger share of the market.

India imports Heparin formulations from the United Arab Emirates due to the availability of patented formulations and specialized dosage forms not produced domestically. The United Arab Emirates's manufacturing facilities adhere to international quality standards, ensuring the safety and efficacy of the products.

Compared to other suppliers like China, Germany, and the United States, the United Arab Emirates offers competitive pricing and high-quality Heparin formulations. The proximity of the United Arab Emirates to India also reduces shipping times and costs, providing a logistical advantage.

Potential risks for Indian importers include currency fluctuations, regulatory changes in the United Arab Emirates, and shipping disruptions. To mitigate these risks, importers should establish strong relationships with suppliers, monitor regulatory developments, and maintain adequate inventory levels.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.
5. 5Regulatory Compliance: Stay updated on regulatory changes in both India and the United Arab Emirates to ensure continuous compliance.

1. 1DGFT Import License: Obtain a valid Drug Import License from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation, including submission of Form 40/41.
3. 3NOC: Secure a No Objection Certificate from the Ministry of Health and Family Welfare if required.
4. 4Customs Broker: Engage a licensed customs broker to facilitate import clearance.
5. 5Advance Ruling: Seek an advance ruling from the Customs Department for HS Code 30049099 to confirm duty rates and classification.

1. 1Certificate of Analysis (CoA): Verify the quality and specifications of the product.
2. 2Certificate of Pharmaceutical Product (CoPP): Confirm the product's compliance with international standards.
3. 3Good Manufacturing Practice (GMP) Certificate: Ensure the manufacturing facility adheres to recognized quality standards.
4. 4Drug Master File (DMF): Provide detailed information about the manufacturing process and quality control measures.
5. 5Stability Data: Include stability studies conducted under ICH Zone IVa/IVb conditions.
6. 6Free Sale Certificate: Indicate that the product is freely sold in the country of origin.
7. 7Manufacturer Authorization: Authorize the Indian importer to import and distribute the product.